Hurley Capital’s Edwards Lifesciences EW Stock Holding History

Hurley Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10	Closed	-$778	–	653
2025 Q3	$778	Buy	+10	New	+$781	﹤0.01%	556

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Hurley Capital's EW Position: Q4 2025 in Review

Hurley Capital sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 10 shares — an estimated $778 sold.

Hurley Capital first reported a position in EW in Q3 2025 and held it in 1 quarter. The position peaked at $778 in Q3 2025. 1,313 funds tracked by Wall St. Rank hold EW as of Q4 2025.

Hurley Capital reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
Hurley Capital sold 10 Edwards Lifesciences shares in Q4 2025, an estimated $778.
Hurley Capital first reported a position in Edwards Lifesciences in Q3 2025 and held it in 1 quarter.
Hurley Capital's Edwards Lifesciences position peaked at $778 in Q3 2025.
1,313 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Hurley Capital's 13F filing for Q4 2025, filed 17 Feb 2026.